Results 121 to 130 of about 392,226 (299)

Biomimetic Copper‐Doped Nano‐Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia

Advanced Healthcare Materials, EarlyView.
We developed a novel copper‐doped aluminum nano‐adjuvant (CuNA) to overcome cytarabine resistance in acute myeloid leukemia (AML). CuNA effectively sensitizes drug‐resistant AML cells to cytarabine by inducing mitochondrial dysfunction and inhibiting HMGCR/GPX4 to amplify ferroptosis.
Chao He, Lingxiao Zhang, Yue Xiong, Yu Wang, Yuqing Zeng, Dandan Su, Ran Wang, Ying Li, Hongbo Chen, Fang Cheng, Zhi Ping Xu   +10 more
wiley   +1 more source

Survival benefits of postoperative adjuvant chemotherapy in adults aged ≥ 80 years with locally advanced gastric cancer: insights from a population-based study

Discover Oncology
Background and aims Postoperative adjuvant chemotherapy in older adults aged ≥ 80 years with locally advanced gastric cancer (LAGC) remains debated owing to concerns over treatment tolerance and limited data.
Fuhai Ma, Yangyang Zheng, Jian Cui, Zijian Li, Jinxin Shi, Tianming Ma, Xianglong Cao, Tao Yu, Guoju Wu, Gang Zhao, Jinghai Song, Qi An   +11 more
doaj   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

Impact of timing of adjuvant chemotherapy on survival for early-stage node-negative small-cell lung cancerCentral MessagePerspective

JTCVS Open
Background: The relationship between timing of adjuvant chemotherapy and survival for early-stage, node-negative small cell lung cancer is not well defined, and no formal guidelines exist. We sought to evaluate whether increasing the time between surgery
Arian Mansur, MD, Adele J. Lee, BA, Alexandra L. Potter, BS, Jacob M. Sands, MD, Catherine B. Meador, MD, PhD, Michael Lanuti, MD, Chi-Fu Jeffrey Yang, MD   +6 more
doaj   +1 more source

Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects

Advanced Materials, EarlyView.
Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley   +1 more source

Cold Atmospheric Plasma‐Activated Decellularized Extracellular Matrix Gel as a Tumor‐Infiltrating Immunoactivation Platform for Post‐Surgical Cancer Immunotherapy

Advanced Materials, EarlyView.
An injectable cold atmospheric plasma‐activated decellularized tumor extracellular matrix hydrogel is introduced as a post‐surgical immunoactivation platform. The engineered gel attracts residual tumor cells and induces immunogenic cell death, reshaping the tumor microenvironment and eliciting systemic antitumor immunity. In combination with checkpoint
Tianxu Fang, Mo Chen, Yueyang Deng, Tianqin Ning, Tianwen Luo, Guojun Chen   +5 more
wiley   +1 more source

Adjuvant chemotherapy

European Journal of Cancer Supplements, 2013
David B. Abrams, J. Rick Turner, Linda C. Baumann, Alyssa Karel, Susan E. Collins, Katie Witkiewitz, Terry Fulmer, Molly L. Tanenbaum, Persis Commissariat, Elyse Kupperman, Rachel N. Baek, Jeffrey S. Gonzalez, Nicole Brandt, Rachel Flurie, Jennifer Heaney, Christopher Kline, Linda Carroll, Jane Upton, Patrícia Cardoso Buchain, Adriana Dias Barbosa Vizzotto, Alexandra Martini de Oliveira, Tania C. T. Ferraz Alves, Quirino Cordeiro, Lorenzo Cohen, M. Kay Garcia, Amy Jo Marcano-Reik, Siqin Ye, Yori Gidron, Marc D. Gellman, M. Bryant Howren, Manjunath Harlapur, Daichi Shimbo, Keisuke Ohta, Naoya Yahagi, Elizabeth Franzmann, Abanish Singh, Linda C. Baumann, Alyssa Karel, Debra Johnson, Benjamin L. Clarke, Debra Johnson, Rachel Millstein, Karen Niven, Karen Niven, Eleanor Miles, J. Rick Turner, Barbara Resnick, Yori Gidron, Carter A. Lennon, Kelly S. DeMartini, Kristin L. MacGregor, Susan E. Collins, Megan Kirouac, J. Rick Turner, Abanish Singh, Yori Gidron, Yoshiharu Yamamoto, Urs M. Nater, Nicole Nisly, Debra Johnson, Derek Johnston, Ydwine Zanstra, Derek Johnston, Youngmee Kim, Della Matheson, Brooke McInroy, Christopher France, Shin Fukudo, Emiko Tsuchiya, Yoko Katayori, Martin Deschner, Norman B. Anderson, Chad Barrett, Mark A. Lumley, Lindsay Oberleitner, Stephan Bongard, Siqin Ye, Amy Jo Marcano-Reik, Seth Hurley, Seth Hurley, Anna Maria Patino-Fernandez, Anna C. Phillips, Tatsuo Akechi, Anna C. Phillips, Amy Jo Marcano-Reik, Nicole Brandt, Rachel Flurie, Sarah Aldred, Kim Lavoie, Manjunath Harlapur, Daichi Shimbo, Kate L. Jansen, Katherine T. Fortenberry, Molly S. Clark, Rachel Millstein, Toru Okuyama, William Whang, Mustafa Al’Absi, Bingshuo Li, Yori Gidron, J. Rick Turner, Elizabeth R. Pulgaron, Diana Wile, Linda C. Baumann, Alyssa Karel, Beth Schroeder, Mary C. Davis, Alex Zautra, Shannon L. Stark, William Whang, Ana Victoria Soto, Yori Gidron, Anthony J. Wheeler, Scott DeBerard, Josh Allen, Akihisa Mitani, Akihisa Mitani, Elizabeth R. Pulgaron, Akihisa Mitani, Jennifer Carter, William Whang, Beth Schroeder, Angela M. Hicks, Carolyn Korbel, Austin S. Baldwin, Kevin S. Spink, Darren Nickel, Michael Richter, Rex A. Wright, Julian F. Thayer, Michael Richter, Rex A. Wright, Deborah J. Wiebe   +132 more
openaire   +3 more sources

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Long-term prognosis and management of hepatocellular carcinoma after curative treatment [PDF]

Clinical and Molecular Hepatology, 2020
Naoshi Nishida
doaj   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source